Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy.
Barki-Harrington L, Baron-Epel O, Shaulov A, Akria L, Barshay Y, Dally N, Deshet D, Inbar T, Koren-Michowitz M, Leiba M, Moshe Y, Shvidel L, Tadmor T, Yagenah S, Zektser M, Preis M, Hellman I, Yahalom V, Aviv A. Barki-Harrington L, et al. Palliat Med. 2021 May;35(5):927-932. doi: 10.1177/02692163211000634. Epub 2021 Mar 24. Palliat Med. 2021. PMID: 33761783 Free PMC article.
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
Berger T, Rozovski U, Moshe Y, Yaari S, Frisch A, Hellmann I, Apel A, Aviram A, Koren-Michowitz M, Yeshurun M, Ram R, Raanani P, Ofran Y, Wolach O. Berger T, et al. Ann Hematol. 2019 Dec;98(12):2711-2717. doi: 10.1007/s00277-019-03795-8. Epub 2019 Sep 11. Ann Hematol. 2019. PMID: 31512015 Clinical Trial.
BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.
Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM. Zuckerman T, et al. Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468. Blood Adv. 2019. PMID: 31770437 Free PMC article. Clinical Trial.
Safety and efficacy of blinatumomab: a real world data.
Apel A, Ofran Y, Wolach O, Shimony S, Ram R, Levi I, Zektser M, Koren-Michowitz M. Apel A, et al. Ann Hematol. 2020 Apr;99(4):835-838. doi: 10.1007/s00277-019-03854-0. Epub 2020 Feb 20. Ann Hematol. 2020. PMID: 32076826
Venetoclax is safe and efficacious in relapsed/refractory AML.
Ganzel C, Ram R, Gural A, Wolach O, Gino-Moor S, Vainstein V, Nachmias B, Apel A, Koren-Michowitz M, Pasvolsky O, Yerushalmi R, Danylesko I, Cohen Y, Peretz G, Moshe Y, Zektser M, Yeganeh S, Rowe JM, Ofran Y. Ganzel C, et al. Leuk Lymphoma. 2020 Sep;61(9):2221-2225. doi: 10.1080/10428194.2020.1761964. Epub 2020 May 18. Leuk Lymphoma. 2020. PMID: 32420775
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A, Moshe Y, Ofran Y, Gural A, Wolach O, Ganzel C, Canaani J, Zektser M, Duek A, Stemer G, Hellman I, Basood M, Frisch A, Leibovitch C, Koren-Michowitz M. Apel A, et al. Am J Hematol. 2021 Jul 1;96(7):790-795. doi: 10.1002/ajh.26190. Epub 2021 Apr 29. Am J Hematol. 2021. PMID: 33836555 Free article.
80 results